U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Unknown
139594
Substance Class Protein
Created
by admin
on Sat Dec 16 05:16:59 UTC 2023
Edited
by admin
on Sat Dec 16 05:16:59 UTC 2023
Protein Type ENZYME
Protein Sub Type CYTOCHROME P450
Sequence Origin HUMAN
Sequence Type COMPLETE
Record UNII
VK4SQL11C0
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CYTOCHROME P450 1A2
Common Name English
CYTOCHROME P450-P3
Common Name English
CYP1A2
Common Name English
CYTOCHROME P(3)450
Common Name English
HUMAN CYTOCHROME P450 1A2
Common Name English
CYTOCHROME P 450 1A2
Common Name English
Code System Code Type Description
CAS
165885-24-5
Created by admin on Sat Dec 16 05:17:09 UTC 2023 , Edited by admin on Sat Dec 16 05:17:09 UTC 2023
PRIMARY
UNIPROT
P05177
Created by admin on Sat Dec 16 05:17:09 UTC 2023 , Edited by admin on Sat Dec 16 05:17:09 UTC 2023
PRIMARY
FDA UNII
VK4SQL11C0
Created by admin on Sat Dec 16 05:17:09 UTC 2023 , Edited by admin on Sat Dec 16 05:17:09 UTC 2023
PRIMARY
Related Record Type Details
Structure of TAFENOQUINE
INHIBITOR -> METABOLIC ENZYME
Ki
Structure of PIMOBENDAN
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of DEFERASIROX
SUBSTRATE -> METABOLIC ENZYME
Structure of SULFORAPHANE
INHIBITOR -> METABOLIC ENZYME
Inhibits both CYP2E1 and CYP1A2-mediated genotoxicity therefore is relevant to human isoforms of these enzymes and may contribute to a chemopreventative activity of brocolli and related species.
Structure of ALOSETRON
SUBSTRATE -> METABOLIC ENZYME
Alosetron is metabolized by human microsomal cytochrome P450 (CYP), shown in vitro to involve enzymes 2C9 (30%), 3A4 (18%), and 1A2 (10%).
MAJOR
Structure of OLANZAPINE
SUBSTRATE -> METABOLIC ENZYME
Structure of GDC-0425
SUBSTRATE -> METABOLIC ENZYME
Structure of RUCAPARIB
INHIBITOR -> METABOLIC ENZYME
REVERSIBLE
Structure of STIRIPENTOL
INHIBITOR -> METABOLIC ENZYME
Structure of ACETAMINOPHEN
SUBSTRATE -> METABOLIC ENZYME
Structure of ALVESPIMYCIN
SUBSTRATE -> METABOLIC ENZYME
Structure of EAPB-0503
SUBSTRATE -> METABOLIC ENZYME
Structure of Belumosudil
INHIBITOR -> METABOLIC ENZYME
Inhibits at clinically relevant concentrations.
Structure of TERIFLUNOMIDE
NON-SUBSTRATE -> METABOLIC ENZYME
Structure of EXEMESTANE
SUBSTRATE -> METABOLIC ENZYME
Structure of VILOXAZINE
INHIBITOR -> METABOLIC ENZYME
REVERSIBLE
CYTOCHROME P450 1A2 (CANINE)
ANIMAL ORTHOLOG->HUMAN ORTHOLOG
Structure of TRILACICLIB
INDUCER -> METABOLIC ENZYME
Structure of 2,3,7-TRICHLORODIBENZO-P-DIOXIN
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of Desloratadine
NON-INHIBITOR -> METABOLIC ENZYME
Structure of DIPHENHYDRAMINE
SUBSTRATE -> METABOLIC ENZYME
CYP1A2, CYP2C9, and CYP2C19 are involved in the metabolism of diphenhydramine as low-affinity P450 isozymes.
Structure of LONAFARNIB
SUBSTRATE -> METABOLIC ENZYME
IN VITRO
Structure of MKC-963
SUBSTRATE -> METABOLIC ENZYME
Structure of CHLORPYRIFOS
INHIBITOR -> METABOLIC ENZYME
Chlorpyrifos inhibited CYP1A1/2 activities more than 90%.
Structure of ETHINYL ESTRADIOL
SUBSTRATE -> METABOLIC ENZYME
Structure of OSU-6162
SUBSTRATE -> METABOLIC ENZYME
Structure of ZIMLOVISERTIB
NON-INHIBITOR -> METABOLIC ENZYME
Structure of NAPROXEN
SUBSTRATE -> METABOLIC ENZYME
Structure of OBETICHOLIC ACID
INHIBITOR OF EXPRESSION->METABOLIC ENZYME
The effect of 10 mg OCA on CYP1A2 substrate caffeine showed that systemicexposure to caffeine increased by 42%. The systemic exposure to caffeine increased by 65% following 25 mg OCA.
Structure of OSILODROSTAT
INHIBITOR -> METABOLIC ENZYME
MODERATE INHIBITION
Structure of THEOPHYLLINE
SUBSTRATE -> METABOLIC ENZYME
Structure of C-1311
INHIBITOR -> METABOLIC ENZYME
time- and concentration-dependent inhibitor
Structure of PIRFENIDONE
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of MDMC
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of EDARAVONE
INDUCER -> METABOLIC ENZYME
Edaravone inhib it e d CYP2C9, BCRP, OAT3, and induced CYP1A2 in vitro.
Structure of SARIZOTAN
SUBSTRATE -> METABOLIC ENZYME
Structure of GNE-0877
INHIBITOR -> METABOLIC ENZYME
Structure of ROFECOXIB
SUBSTRATE -> METABOLIC ENZYME
Structure of ZILEUTON
SUBSTRATE -> METABOLIC ENZYME
Structure of Tuspetinib
SUBSTRATE -> METABOLIC ENZYME
Structure of LANSOPRAZOLE
INDUCER -> METABOLIC ENZYME
Structure of C-1330
INHIBITOR -> METABOLIC ENZYME
Structure of LUMATEPERONE
SUBSTRATE -> METABOLIC ENZYME
Structure of CRISABOROLE
SUBSTRATE -> METABOLIC ENZYME
Structure of LORCASERIN
SUBSTRATE -> METABOLIC ENZYME
Structure of ROPIVACAINE
SUBSTRATE -> METABOLIC ENZYME
Structure of TACRINE
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of NAPHTHALENE
SUBSTRATE -> METABOLIC ENZYME
Structure of TEGASEROD
INHIBITOR -> METABOLIC ENZYME
Ki
Structure of 3-ISOXAZOLECARBOXAMIDE, N-(2,4-DICHLOROPHENYL)-5-METHYL-
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of CIMETIDINE
INHIBITOR -> METABOLIC ENZYME
POTENT
Structure of TRICLABENDAZOLE SULFOXIDE
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of DEUTETRABENAZINE
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of 2-AMINO-1-METHYL-6-PHENYLIMIDAZO(4,5-B)PYRIDINE
SUBSTRATE -> METABOLIC ENZYME
Structure of WARFARIN, (R)-
SUBSTRATE -> METABOLIC ENZYME
Structure of DRONABINOL
INHIBITOR -> METABOLIC ENZYME
Structure of ANAGRELIDE
SUBSTRATE -> METABOLIC ENZYME
Structure of CINACALCET
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of LOMITAPIDE
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of SILIBININ A
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of TAPINAROF
SUBSTRATE -> METABOLIC ENZYME
EC50
Structure of VELIPARIB
SUBSTRATE -> METABOLIC ENZYME
Structure of TROPISETRON
SUBSTRATE -> METABOLIC ENZYME
Structure of ANETHOLTRITHION
SUBSTRATE -> METABOLIC ENZYME
Structure of ORANTINIB
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of PIGMENT YELLOW 74
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of SULINDAC
SUBSTRATE -> METABOLIC ENZYME
Structure of ZOLPIDEM
SUBSTRATE -> METABOLIC ENZYME
Structure of ALLITINIB
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of FLIBANSERIN
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of MALATHION
INHIBITOR -> METABOLIC ENZYME
Malathion inhibited CYP1A1/2 activities more than 90%.
Structure of PARATHION
SUBSTRATE -> METABOLIC ENZYME
Structure of JANEX-1
SUBSTRATE -> METABOLIC ENZYME
Structure of ENASIDENIB
SUBSTRATE -> METABOLIC ENZYME
Structure of CIPROFLOXACIN
INHIBITOR -> METABOLIC ENZYME
POTENT
Structure of ENZALUTAMIDE
INHIBITOR -> METABOLIC ENZYME
TIME-DEPENDENT INHIBITION
Structure of 4'-METHYL-.ALPHA.-PYRROLIDINOBUTIOPHENONE
SUBSTRATE -> METABOLIC ENZYME
HUMAN LIVER
TISSUE EXPRESSION -> PARENT
Structure of LOFEXIDINE
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of NABUMETONE
SUBSTRATE -> METABOLIC ENZYME
Structure of BRANEBRUTINIB
INHIBITOR -> METABOLIC ENZYME
Structure of TIZANIDINE
SUBSTRATE -> METABOLIC ENZYME
Structure of SONIDEGIB
NON-INDUCER -> METABOLIC ENZYME
compared to positive controls
Structure of E-NORENDOXIFEN
INHIBITOR -> METABOLIC ENZYME
E-Norendoxifen inhibited CYP1A2 2.0-fold more potently than Z-norendoxifen.
Structure of OXYMETAZOLINE
NON-SUBSTRATE -> METABOLIC ENZYME
Structure of PF-06835919
NON-INHIBITOR -> METABOLIC ENZYME
IC50
Structure of CARVEDILOL
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of DAPSONE
SUBSTRATE -> METABOLIC ENZYME
Structure of TRICLABENDAZOLE SULFONE
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of ELTROMBOPAG
SUBSTRATE -> METABOLIC ENZYME
Structure of IMIPRAMINE
SUBSTRATE -> METABOLIC ENZYME
10%-20% OF TOTAL METABOLISM
Structure of 2,4-DICHLOROANILINE
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of ANTIPYRINE
SUBSTRATE -> METABOLIC ENZYME
Structure of APOMORPHINE
INDUCER -> METABOLIC ENZYME
MAXIMUM FOLD INCREASE
Structure of TRICLABENDAZOLE
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of PRALSETINIB
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of CAFFEINE
INDUCER -> METABOLIC ENZYME
Structure of AMIODARONE
INHIBITOR -> METABOLIC ENZYME
POTENT
Structure of FEBUXOSTAT
SUBSTRATE -> METABOLIC ENZYME
Structure of RUCAPARIB
INDUCER -> METABOLIC ENZYME
Structure of DIETHYLTOLUAMIDE
SUBSTRATE -> METABOLIC ENZYME
Structure of VERUBECESTAT
NON-INHIBITOR -> METABOLIC ENZYME
Structure of S-16020
SUBSTRATE -> METABOLIC ENZYME
Structure of CLOZAPINE
SUBSTRATE -> METABOLIC ENZYME
Structure of VERUBECESTAT
NON-INDUCER -> METABOLIC ENZYME
Structure of MIDOMAFETAMINE
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of NOMIFENSINE
SUBSTRATE -> METABOLIC ENZYME
Structure of FROVATRIPTAN
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of PHENACETIN
SUBSTRATE -> METABOLIC ENZYME
Structure of KB-0742
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of ASENAPINE
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of MOMELOTINIB
SUBSTRATE -> METABOLIC ENZYME
Structure of DAPTOMYCIN
NON-INHIBITOR -> METABOLIC ENZYME
Structure of RIFAMYCIN
INHIBITOR -> METABOLIC ENZYME
Rifamycin is an inhibitor of CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A4/5 in vitro, however, based on systemic concentrations of rifamycin observed after administration of the recommended dose clinically relevant inhibition of these enzymes in vivo is unlikely.
Structure of UAB-30
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of NE-100 FREE BASE
SUBSTRATE -> METABOLIC ENZYME
Structure of RILUZOLE
SUBSTRATE -> METABOLIC ENZYME
Structure of IXAZOMIB
SUBSTRATE -> METABOLIC ENZYME
Structure of VOXILAPREVIR
SUBSTRATE -> METABOLIC ENZYME
Structure of ETORICOXIB
SUBSTRATE -> METABOLIC ENZYME
Structure of SONIDEGIB
NON-INHIBITOR -> METABOLIC ENZYME
No time dependent inhibition upto 50 micromolar
Structure of 2-(3-FLUOROPHENYL)-5-HYDROXY-6-METHOXY-4(1H)-QUINOLINONE
INHIBITOR -> METABOLIC ENZYME
Structure of ISTRADEFYLLINE
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of PROPANAMIDE, N-(5-(2-(2-METHOXY-3-PYRIDINYL)-7-METHYLIMIDAZO(1,2-A)PYRIDIN-3-YL)-6-(2-(1-METHYL-6-ISOQUINOLINYL)ETHYNYL)-2-PYRIDINYL)-2-(METHYLAMINO)-, (2S)-
INHIBITOR -> METABOLIC ENZYME
Structure of CARBAMAZEPINE
INDUCER -> METABOLIC ENZYME
Structure of .ALPHA.-PYRROLIDINOPENTIOPHENONE
SUBSTRATE -> METABOLIC ENZYME
Structure of EAPB-0203
SUBSTRATE -> METABOLIC ENZYME
Structure of RASAGILINE
SUBSTRATE -> METABOLIC ENZYME
Structure of BORTEZOMIB
SUBSTRATE -> METABOLIC ENZYME
Structure of COBICISTAT
NON-INHIBITOR -> METABOLIC ENZYME
Structure of RAMELTEON
SUBSTRATE -> METABOLIC ENZYME
Structure of ABAMETAPIR
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of RIFAMPIN
INDUCER -> METABOLIC ENZYME
POTENT
Structure of ENCORAFENIB
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of CYCLOBENZAPRINE
SUBSTRATE -> METABOLIC ENZYME
Structure of VILOXAZINE
INDUCER -> METABOLIC ENZYME
Structure of POMALIDOMIDE
SUBSTRATE -> METABOLIC ENZYME
Structure of SELEGILINE
SUBSTRATE -> METABOLIC ENZYME
Structure of PF-06821497
NON-INHIBITOR -> METABOLIC ENZYME
Structure of GABAPENTIN ENACARBIL
NON-SUBSTRATE -> METABOLIC ENZYME
Structure of TASIMELTEON
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of OTESECONAZOLE
NON-INHIBITOR -> METABOLIC ENZYME
Structure of TETRABENAZINE
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of MDE
MDE
SUBSTRATE -> METABOLIC ENZYME
Structure of GNE-0877
INDUCER -> METABOLIC ENZYME
Structure of ALVAMELINE
SUBSTRATE -> METABOLIC ENZYME
Structure of PHENTHOATE
INHIBITOR -> METABOLIC ENZYME
Phenthoate inhibited CYP1A1/2 activities more than 90%.
Structure of METHOXYCHLOR
SUBSTRATE -> METABOLIC ENZYME
Structure of PALONOSETRON
SUBSTRATE -> METABOLIC ENZYME
Structure of CAFFEINE
SUBSTRATE -> METABOLIC ENZYME
Structure of BUTYLPHTHALIDE
SUBSTRATE -> METABOLIC ENZYME
Structure of RUCAPARIB
SUBSTRATE -> METABOLIC ENZYME
In vitro, rucaparib was metabolized primarily by CYP2D6 and to a lesser extent by CYP1A2 and CYP3A4.
Structure of ALDUMASTAT
SUBSTRATE -> METABOLIC ENZYME
Structure of FENITROTHION
INHIBITOR -> METABOLIC ENZYME
Fenitrothion inhibited CYP1A1/2 activities more than 90%.
Structure of SELUMETINIB
SUBSTRATE -> METABOLIC ENZYME
Structure of Binimetinib
SUBSTRATE -> METABOLIC ENZYME
Structure of DACARBAZINE
SUBSTRATE -> METABOLIC ENZYME
Structure of ATAZANAVIR
INHIBITOR -> METABOLIC ENZYME
COMPETITIVE INHIBITOR
Ki
Structure of UMBRALISIB
SUBSTRATE -> METABOLIC ENZYME
Structure of PARATHION-METHYL
SUBSTRATE -> METABOLIC ENZYME
Structure of OTESECONAZOLE
INDUCER -> METABOLIC ENZYME
mRNA levels in at least 2 hepatocyte cultures. Up 10 micromolar OTESECONAZOLE
Structure of Roflumilast
SUBSTRATE -> METABOLIC ENZYME
Structure of TRAMADOL
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of ROFECOXIB
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of NORENDOXIFEN
INHIBITOR -> METABOLIC ENZYME
E-Norendoxifen inhibited CYP1A2 2.0-fold more potently than Z-norendoxifen.
Structure of RIVOGLITAZONE
SUBSTRATE -> METABOLIC ENZYME
Structure of ORANTINIB
INDUCER -> METABOLIC ENZYME
Structure of ABIRATERONE
INHIBITOR -> METABOLIC ENZYME
In vitro studies with human hepatic microsomes showed that abiraterone has the potential to inhibit CYP1A2, CYP2D6, CYP2C8 and to a lesser extent CYP2C9, CYP2C19 and CYP3A4/5.
Structure of PRACINOSTAT
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of OMEPRAZOLE
INDUCER -> METABOLIC ENZYME
Structure of APREPITANT
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of TRICLABENDAZOLE
INHIBITOR -> METABOLIC ENZYME
Structure of DULOXETINE
SUBSTRATE -> METABOLIC ENZYME
Structure of PROFENOFOS
INHIBITOR -> METABOLIC ENZYME
Profenofos inhibited CYP1A1/2 activities more than 90%.
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
Molecular Formula CHEMICAL
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966